Engitix Therapeutics

Biotechnology ResearchEngland, United Kingdom51-200 Employees

Engitix Therapeutics is a biotechnology research company that uses a human extracellular matrix–based discovery platform to advance therapies for fibrosis and solid tumours. It develops a portfolio of programmes and employs human in vitro models that mimic the natural cell microenvironment to identify drug targets, clarify mechanisms of action, and profile candidate medicines. By providing more physiologically relevant models, the approach aims to improve early assessment of efficacy and reduce late-stage clinical failures, benefiting pharmaceutical and biotech researchers seeking more predictive discovery tools.

Headquartered in London, England, Engitix describes itself as a mid-sized player in the biotechnology research landscape, focusing on tissue- and disease-specific ECM scaffolds to study disease mechanisms. In 2026 the company announced a collaboration with GSK to develop therapies aimed at liver fibrosis regression, reflecting active industry partnerships. Its recent work includes developing human ECM–based disease models and generating translational multi-omics data to uncover targets associated with fibrosis resolution in liver disease.

Sign up for free to view info

Email Format Employee directory